Literature DB >> 12075822

Polyester microparticles as a vaccine delivery system for brucellosis: influence of the polymer on release, phagocytosis and toxicity.

M Murillo1, C Gamazo, J M Irache, M M Goñi.   

Abstract

Microparticles, containing an antigenic complex from Brucella ovis (HS), were evaluated for vaccine purposes against brucellosis. They were prepared by the double emulsion solvent evaporation method using two different polyesters, poly-lactide-co-glycolide acid (75:25; RG 756) and poly-epsilon-caprolactone. The encapsulation efficiency and release of HS from the microparticles, their capacity to be phagocytosed and also their toxicity on murine monocytes J774.2 were investigated. Both polymers lead to smooth and spherical sub-5 microm particles, with approximately 30% of the antigen initial dose encapsulated. SDS-PAGE and immunoblot of extracted antigens confirmed that the apparent molecular weight and antigenicity remained unaltered after the encapsulation procedure. However, the in vitro release of the antigens differed among them. The release profile for PLGA microparticles was continuous, whereas PEC ones released the antigens in a triphasic release pattern. Phagocytosis was clearly influenced by the hydrophobicity of the polymer, increasing in the case of PEC microparticles. Toxicity assay showed that both types of microparticles induced similar levels of mitochondrial damage. In conclusion, HS-PEC microparticles could be used as an effective vaccine against brucellosis, as the antigen is released in boosters and they are greatly phagocytosed by macrophages.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12075822     DOI: 10.1080/10611860290022642

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  4 in total

1.  Stability of poly(epsilon-caprolactone) microparticles containing Brucella ovis antigens as a vaccine delivery system against brucellosis.

Authors:  Maite Estevan; Carlos Gamazo; Fernando Martínez-Galan; Juan M Irache
Journal:  AAPS PharmSciTech       Date:  2008-10-16       Impact factor: 3.246

2.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

3.  The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle.

Authors:  A M Arenas-Gamboa; T A Ficht; M M Kahl-McDonagh; G Gomez; A C Rice-Ficht
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

Review 4.  Nanoparticulate adjuvants and delivery systems for allergen immunotherapy.

Authors:  Juliana De Souza Rebouças; Irene Esparza; Marta Ferrer; María Luisa Sanz; Juan Manuel Irache; Carlos Gamazo
Journal:  J Biomed Biotechnol       Date:  2012-02-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.